Please login to the form below

Not currently logged in
Email:
Password:

NTDT

This page shows the latest NTDT news and features for those working in and with pharma, biotech and healthcare.

Novartis' Exjade gets EU approval for thalassaemia

Novartis' Exjade gets EU approval for thalassaemia

Novartis' Exjade (deferasirox) has received European approval as a treatment for non-transfusion-dependent thalassaemia (NTDT) syndromes, a group of genetic disorders characterised by red blood cell problems and anaemia. ... This approval is a critical

Latest news

  • CHMP backs Novartis' Bexsero, Exjade CHMP backs Novartis' Bexsero, Exjade

    It was approved in Europe in March, 2010. Thalassaemia candidate. Meanwhile, the CHMP also gave its backing to Novartis' Exjade (deferasirox) as a treatment for non-transfusion-dependent thalassaemia (NTDT) syndromes, ... Clinical trials have shown

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics